Labcorp has expanded its DPYD Genotyping test to detect all DPYD gene variants recommended by the Association for Molecular Pathology, helping identify cancer patients at risk of severe side effects from fluoropyrimidine chemotherapy. This test supports personalized cancer treatment by identifying patients who may experience life-threatening toxicity from drugs like 5-fluorouracil and capecitabine. The FDA now includes warnings about these risks and recommends DPYD testing before treatment. Labcorp's expanded test enhances its pharmacogenomics portfolio, aiding safer, tailored cancer care.
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
